ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual,
Chapter 2 - Immunization Program,
Section III - Immunization of Special Populations & Section VII - Biological Products

Section III – Immunization of Special Populations

1.0 Immunocompromised Individuals:

1.4.2 Referral Form For Varicella Vaccination & 1.4.3 Referral Form For MMR Vaccination

- Hyperlink added to downloadable versions of each form.
- ‘Nurse Practitioner’ has been added as a health care provider who may provide approval for an immunocompromised client to receive varicella and/or MMR vaccine.
- Time interval for receipt of varicella and/or MMR vaccine prior to solid organ transplant changed from 6 weeks to 4 weeks.
- Content for malignant disease specified for “adults” and language changed from “…being cured of a malignant disease…” to “…no longer immunocompromised by malignant disease…”
- Any content related to the scheduling of varicella and/or MMR vaccination for a particular health condition has been removed from the footnotes, as the intent is to keep this as a ‘referral form’. Content related to immunization scheduling for a specific health condition is contained in the respective subsections of Section III, and therefore a link to Section III has been added below the table to inform the physician/nurse practitioner where this information can be found.
- Date, client name, DOB and PHN number has been added to the second page of each referral form.
- The time frame for which the referral form must be renewed by the physician or nurse practitioner has been changed from 3 months to 4 months.
- ‘PHN initials’ removed from the PHN documentation section on the second page of each referral form.

Please remove page numbers: 10-11a dated February 2013
Please add new page numbers: 10-11a dated May 2016
1.4.4 Referral Form For Rotavirus Vaccination

- Hyperlink added to downloadable version of the form.
- ‘Nurse Practitioner’ has been added as a health care provider who may provide approval for an immunocompromised client to receive rotavirus vaccination.

Please remove page number: 11b dated May 2015
Please add new page number: 11b dated May 2016

1.5.1 Anatomic or Functional Asplenia

- Meningococcal vaccine updated to recommend meningococcal quadrivalent conjugate vaccine (Men-C-ACYW-135) for individuals 2 months of age and older. For children, Men-C-ACYW-135 would be given in place of Men-C-C as part of the routine childhood immunization schedule.
- Influenza vaccine updated to recommend that inactivated influenza vaccine should be used.
- Rotavirus vaccine added.
- Varicella vaccine updated to recommend 12 weeks between doses.
- MMR and varicella updated to recommend that separate MMR and varicella vaccines should be used, separated by an interval of 4 weeks. MMRV vaccine is contraindicated.
- Content relating to the timing interval for immunization before and after splenectomy updated and moved to footnotes.

Please remove page numbers: 12 & 13 dated November 2010 & June 2009
Please add new page numbers: 12 & 13 dated May 2016

1.5.2 Congenital Immunodeficiency States

- Meningococcal vaccine updated to recommend meningococcal quadrivalent conjugate vaccine (Men-C-ACYW-135) for individuals 2 months of age and older. For children, Men-C-ACYW-135 would be given in place of Men-C-C as part of the routine childhood immunization schedule.
- Hib vaccine updated to recommend Hib vaccine for all individuals 5 years of age and older regardless of immunization history.
- Influenza vaccine updated to recommend that inactivated influenza vaccine should be used.
- Varicella vaccine updated to recommend 12 weeks between the two doses.
- MMR and varicella updated to recommend that separate MMR and varicella vaccines should be used, separated by an interval of 4 weeks. MMRV vaccine is contraindicated.

Please remove page number: 14 dated January 2012
Please add new page numbers: 14 & 14a dated May 2016
1.5.5 Immunosuppressive Therapy

- Influenza vaccine updated to recommend that inactivated influenza vaccine should be used.
- Rotavirus vaccine added.
- ‘Therapeutic monoclonal antibodies’ added to list of examples of long-term immunosuppressive therapy. For a more comprehensive list, a link to the Canadian Immunization Guide has been added.
- ‘1.5.5.2 Infants born to mothers on immunosuppressive medication’ added.

Please remove page numbers: 21 & 22 dated November 2010
Please add new page numbers: 21-22a dated May 2016

1.5.9 Candidate for or Recipient of Solid Organ or Islet Cell Transplant

- Hepatitis B vaccine updated to recommend that the renal formulation be used for kidney transplant candidates and recipients.
- For hepatitis B post immunization testing, content added that candidates/recipients of a kidney transplant should be tested annually as per subsection 1.5.6 Chronic Kidney Disease.
- Influenza vaccine updated to indicate that LAIV is not recommended after transplantation.
- Meningococcal vaccine updated to recommend meningococcal quadrivalent conjugate vaccine (Men-C-ACYW-135) for individuals 2 months of age and older. For children, Men-C-ACYW-135 would be given in place of Men-C-C as part of the routine childhood immunization schedule.
- Varicella vaccine updated to recommend 12 weeks between the two doses.
- Content regarding timing of vaccines revised, including:
  - Receipt of live vaccines prior to transplant changed from 6 weeks to 4 weeks.
  - Inactivated vaccines should be given at least 2 weeks prior to transplant.
- Rotavirus vaccine added.
- Time interval for beginning/resuming immunization after transplantation changed from ‘6-12 months’ to ‘3-6 months’. Influenza vaccine recommendations added.
- Zoster vaccine content added.
- Content added regarding SOT recipients who are treated for rejection using rituximab or anti-lymphocyte treatments (e.g., anti-thymocyte globulin), and deferring immunization until 6 months post-treatment.
- Immunization recommendations for living donors added.
- Table 8: BC Children’s Hospital Multi-organ Transplant Clinic Accelerated Immunization Schedule for Children Expected to be Transplanted Before 18 months of age & Table 9: BC Children’s Hospital Multi-organ Transplant Clinic Routine Immunization Schedule for Children Expected to be Transplanted After 18 months of age updated to reflect current guidelines.

Please remove page numbers: 29-33 dated January 2009-November 2010
Please add new page numbers: 29-33 dated May 2016
2.0 Other Conditions:

2.9 Women Who are Pregnant or Planning a Pregnancy

- Influenza vaccine updated to indicate that this vaccine is recommended at any stage of pregnancy, and live attenuated influenza vaccine is contraindicated.
- Inactivated vaccines have been grouped under “All routine inactivated vaccines”, indicating that Human Papillomavirus (HPV) vaccine is contraindicated during pregnancy.
- Content related to women who receive RhIg postpartum and subsequent receipt of MMR and/or varicella vaccine has been updated to be consistent with Section VII-Biological Products.

Please remove page numbers: 43 & 44 dated January 2010 & January 2009
Please add new page numbers: 43 & 44 dated May 2016

2.10 Infants Born Prematurely

- Influenza vaccine updated to indicate that this vaccine is routinely recommended for children 6-59 months of age.
- Pneumococcal conjugate vaccine (PCV) added, indicating that infants born at 32 weeks gestation or less are at risk of impaired lung function and should be assessed for the need for a 4-dose schedule of PCV, as well as pneumococcal polysaccharide vaccine at 2 years of age.

Please remove page numbers: 45 dated December 2015
Please add new page numbers: 45 & 45a dated May 2016

Please also remove the Table of Contents for Section III – Immunization of Special Populations dated January 2016 and replace with the enclosed updated Table of Contents dated May 2016.

Section VII-Biological Products

Haemophilus b Conjugate Vaccine
Act-HIB®
INDICATIONS updated to include individuals 5 years of age and older with a congenital immunodeficiency regardless of immunization history.

Please remove page number: 4 dated January 2016
Please add new page number: 4 dated May 2016
If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC at telephone (604) 707-2555, fax (604) 707-2515 or by email at christine.halpert@bccdc.ca

Sincerely,

Monika Naus, MD MHSc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc: BC Ministry of Health:
   Dr. Perry Kendall
   Provincial Health Officer

   Dr. Bonnie Henry
   Deputy Provincial Health Officer

   Craig Thompson
   Director of Immunization
   Healthy Populations and Development Branch

   Warren O’Briain
   Executive Director
   Healthy Populations and Development Branch